En forskningsundersøgelse for at se, hvor meget CagriSema sænker blodsukker og kropsvægt sammenlignet med placebo hos mennesker med type 2-diabetes behandlet med kost og motion (REIMAGINE 1)
Effekt og sikkerhed af samtidig administreret Cagrilintide og Semaglutid (CagriSema) s.c. i doser 2,4 mg/2,4 mg og 1,0 mg/1,0 mg én gang om ugen versus placebo hos deltagere med type 2-diabetes utilstrækkeligt kontrolleret på diæt og motion
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
California
-
Huntington Park, California, Forenede Stater, 90255
- Nat Res Inst Huntington Park
-
Northridge, California, Forenede Stater, 91325
- Valley Clinical Trials, Inc.
-
Santa Ana, California, Forenede Stater, 92701
- Southern California Dermatology
-
-
Florida
-
Hollywood, Florida, Forenede Stater, 33024
- Encore Medical Research LLC
-
Orlando, Florida, Forenede Stater, 32819
- Headlands Research Orlando
-
Weston, Florida, Forenede Stater, 33331
- Encore Medical Research of Weston
-
-
Kansas
-
Newton, Kansas, Forenede Stater, 67114
- Alliance for Multispec Res
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Troy, Michigan, Forenede Stater, 48098
- Arcturus HC PLC Troy Med Res
-
-
New York
-
West Seneca, New York, Forenede Stater, 14224
- Southgate Medical Group, LLP
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- Summit Research Network Oregon Inc.
-
-
Tennessee
-
Kingsport, Tennessee, Forenede Stater, 37660
- Holston Medical Group
-
-
Texas
-
Amarillo, Texas, Forenede Stater, 79124
- Amarillo Medical Specialists
-
Austin, Texas, Forenede Stater, 78704
- Elligo Clin Res Centre
-
Brownsville, Texas, Forenede Stater, 78526
- Headlands Research Brownsville
-
Dallas, Texas, Forenede Stater, 75230
- Velocity Clinical Res-Dallas
-
San Antonio, Texas, Forenede Stater, 78233
- Northeast Clinical Research of San Antonio
-
Shavano Park, Texas, Forenede Stater, 78231
- Consano Clinical Research, LLC
-
Sugar Land, Texas, Forenede Stater, 77479
- Sugar Lakes Family Practice PA
-
Weslaco, Texas, Forenede Stater, 78596
- Valley Diab. & Endo Comp Ctr
-
-
Virginia
-
Newport News, Virginia, Forenede Stater, 23606
- TPMG Clinical Research
-
-
-
-
-
Bergamo, Italien, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Catanzaro, Italien, 88100
- Policlinico Mater Domini Università di Catanzaro
-
Milan, Italien, 20132
- IRCCS Ospedale San Raffaele Milano
-
Roma, Italien, 00161
- Azienda Ospealiero Universitaria Policlinico Umberto I
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100853
- Chinese People's Liberation Army General Hospital-Endocrinology
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210011
- The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
-
Zhenjiang, Jiangsu, Kina, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Shandong
-
Ji'Nan, Shandong, Kina, 250000
- Jinan Central Hospital
-
Jinan, Shandong, Kina, 250000
- Jinan Central Hospital
-
-
-
-
-
Bialystok, Polen, 15-351
- Osteo-Medic s.c. A. Racewicz, J. Supronik
-
Bialystok, Polen, 15-797
- Renew Clinic Sp. z o.o.
-
Lodz, Polen, 90-338
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
-
Warsaw, Polen, 02-507
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
-
Warsaw, Polen, 00-710
- NBR Polska Tomasz Klodawski
-
Zamość, Polen, 22-400
- Velocity Nova Sp. z o.o.
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polen, 35-055
- Centrum Medyczne Medyk Sp. z o.o.
-
-
-
-
-
Al Ahsa, Saudi Arabien, 36428
- King Abdulaziz Hospital-Al Ahsa-National Guard
-
Jeddah, Saudi Arabien, 21423
- National Guard Hospital - Jeddah
-
Riyadh, Saudi Arabien, 11525
- King Fahad Medical City
-
Riyadh, Saudi Arabien, 12372
- King Khaled University Hospital,King Saud Univ. Med. City
-
Riyadh, Saudi Arabien, 12769
- King Salman Bin Abdulaziz Hospital
-
-
-
-
-
Belgrade, Serbien, 11080
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade, Serbien, 11080
- Clinical Hospital Centre Zemun
-
Belgrade, Serbien, 11000
- CHC Zvezdara, Clinical department for endocrinology
-
Zaječar, Serbien, 19000
- Policlinic for diabetes
-
-
-
-
-
Budapest, Ungarn, 1032
- Szent Margit Rendelőintézet Nonprofit Kft.
-
Budapest, Ungarn, 1102
- PVN Kutató Kft.
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4025
- Belinus Bt.
-
-
Szabolcs-Szatmar Varmegye
-
Nyíregyháza, Szabolcs-Szatmar Varmegye, Ungarn, 4405
- Borbánya Praxis E.Ü. Kft.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female
- Age 18 years or above at the time of signing the informed consent
- Diagnosed with type 2 diabetes >=30 days before screening
- HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
- Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening
Exclusion Criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
- Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
- Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: CagriSema Dose 2
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Placebo komparator: Placebo Dose 2
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
|
Aktiv komparator: Cagrisema Dose 1
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Placebo komparator: Placebo Dose 1
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as percentage (%)-points. |
From baseline (week 0) to end of treatment (week 40)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Relative change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured in %. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=15% body weight reduction
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Tidsramme: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Tidsramme: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Change in Fasting Plasma Glucose (FPG)
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimoles per liter (mmol/L). |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=5% body weight reduction
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=20% body weight reduction
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in waist circumference
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured in centimeters (cm). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in systolic blood pressure (SBP)
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimeters of mercury (mmHg). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in diastolic blood pressure (DBP)
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured in mmHg. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Total cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Triglycerides
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Free fatty acids
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Non-HDL cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Tidsramme: At end of study (week 52)
|
Measured as count of participants. |
At end of study (week 52)
|
|
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Physical Component Summary score
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Mental Component Summary score
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in leptin
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured in nanograms per milliliter (ng/mL). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in soluble leptin receptor
Tidsramme: From baseline (week 0) to end of treatment (week 40)
|
Measured in ng/mL. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of Treatment Emergent Adverse Events (TEAEs)
Tidsramme: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of events. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Tidsramme: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Tidsramme: From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NN9388-4895
- 2022-502677-42 (Anden identifikator: European Medical Agency (EMA))
- U1111-1283-0404 (Anden identifikator: World Health Organization (WHO))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .